

The G3 Team

Management: Founder and CEO



Szilard Voros, MD, FACC, FSCCT, FAHA
Founder and Chief Executive Officer

- Internist, cardiologist, inventor and entrepreneur

- Recognized international expert in genomics, lipid disorders and non-invasive cardiac imaging
- Helped create scientific platform for Merck's ezetimibe drug; a \$1B+ annual revenue drug to Merck
- Has been the most requested and utilized international speaker by Merck and Merck-Schering Plough for several consecutive years

- Published in the most prestigious scientific journals

- Nature Journals
- Annals of Internal Medicine
- Journal of the American College of Cardiology
- Circulation Genetics
- New England Journal of Medicine

- Early in his career, Voros was developing scientific platform for Schering-Plough/Merck's ezetimibe, a novel, first-in-class cholesterol lowering drug
 - Ezetimibe was discovered by Harry "Chip" Davis, who is G3's Chief Drug Development Officer today
 - Ezetimibe is a \$1B+/year drug for Merck today
- During the same time, Voros's group at the Piedmont Heart Institute in Atlanta became one of the leaders in cardiovascular CT imaging, and Voros and his team developed novel, patented imaging techniques for precision imaging of human cardiovascular disease (U.S. Patent No. 12/643,962; issued in 2014)
- Around 2008/2009, Voros was hired as a consultant by Palo Alto-based, TPG/KPCB-backed CardioDx to help develop a blood-based diagnostic test using gene expression for cardiovascular disease; using Voros's expertise in imaging, biomarker development and utilizing Voros's novel precision imaging approaches, CardioDx was able to launch the very first diagnostic biomarker for cardiovascular disease, CorusCAD™, which was featured at #7 of the Top 10 Medical Breakthroughs by Time Magazine in 2010
- Around 2010-2011, it became clear to Voros that there was an unprecedented opportunity to transform the drug development process and diagnostic blood test development process on the basis of precision medicine, leveraging the measurement of genetic, genomic, proteomic, metabolomic and lipidomic factors simultaneously; there was an opportunity to create a SINGLE company based on Precision Medicine to develop virtually every single potential drug and every single potential blood test that would be developed over the next 5-10 years in cardiovascular, cardio-metabolic and metabolic diseases